|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Jemal A, Grey N, Ferlay J and
Forman D: Global cancer transitions according to the Human
Development Index (2008–2030): A population-based study. Lancet
Oncol. 13:790–801. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sangha R, Price J and Butts CA: Adjuvant
therapy in non-small cell lung cancer: Current and future
directions. Oncologist. 15:862–872. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Raso MG and Wistuba II: Molecular
pathogenesis of early-stage non-small cell lung cancer and a
proposal for tissue banking to facilitate identification of new
biomarkers. J Thorac Oncol. 2(7 Suppl 3): S128–S135. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ranganathan P, Weaver KL and Capobianco
AJ: Notch signalling in solid tumours: A little bit of everything
but not all the time. Nat Rev Cancer. 11:338–351. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rahman MT, Nakayama K, Rahman M, Katagiri
H, Katagiri A, Ishibashi T, Ishikawa M, Iida K, Nakayama S, Otsuki
Y and Miyazaki K: Notch 3 overexpression as potential therapeutic
target in advanced stage chemoresistant ovarian cancer. Am J Clin
Pathol. 138:535–544. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jonusiene V, Sasnauskiene A, Lachej N,
Kanopiene D, Dabkeviciene D, Sasnauskiene S, Kazbariene B and
Didziapetriene J: Down-regulated expression of Notch signaling
molecules in human endometrial cancer. Med Oncol. 30:4382013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mann CD, Bastianpillai C, Neal CP, Masood
MM, Jones DJ, Teichert F, Singh R, Karpova E, Berry DP and Manson
MM: Notch 3 and HEY-1 as prognostic biomarkers in pancreatic
adenocarcinoma. PLoS One. 7:e511192012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kang H, An HJ, Song JY, Kim TH, Heo JH,
Ahn DH and Kim G: Notch 3 and Jagged2 contribute to gastric cancer
development and to glandular differentiation associated with MUC2
and MUC5AC expression. Histopathology. 61:576–586. 2012.PubMed/NCBI
|
|
10
|
Kopan R and Ilagan MX: The canonical Notch
signaling pathway: Unfolding the activation mechanism. Cell.
137:216–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu J, Fan H, Ma Y, Liang D, Huang R, Wang
J, Zhou F, Kan Q, Ming L, Li H, et al: Notch 1 is a 5-fluorouracil
resistant and poor survival marker in human esophagus squamous cell
carcinomas. PLoS One. 8:e561412013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yu B, Wei J, Qian X, Lei D, Ma Q and Liu
Y: Notch 1 signaling pathway participates in cancer invasion by
regulating MMPs in lingual squamous cell carcinoma. Oncol Rep.
27:547–552. 2012.PubMed/NCBI
|
|
13
|
Mitsuhashi Y, Horiuchi A, Miyamoto T,
Kashima H, Suzuki A and Shiozawa T: Prognostic significance of
Notch signalling molecules and their involvement in the
invasiveness of endometrial carcinoma cells. Histopathology.
60:826–837. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Reedijk M, Odorcic S, Chang L, et al:
High-level coexpression of JAG1 and Notch 1 is observed in human
breast cancer and is associated with poor overall survival. Cancer
Res. 65:8530–8537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang J, Fu L, Gu F and Ma YJ: Notch 1 is
involved in migration and invasion of human breast cancer cells.
Oncol Rep. 26:1295–1303. 2011.PubMed/NCBI
|
|
16
|
Bellavia D, Campese AF, Checquolo S, et
al: Combined expression of pTalpha and Notch 3 in T cell leukemia
identifies the requirement of preTCR for leukemogenesis. Proc Natl
Acad Sci U S A. 99:3788–3793. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Serafin V, Persano L, Moserle L, Esposito
G, Ghisi M, Curtarello M, Bonanno L, Masiero M, Ribatti D, Stürzl
M, et al: Notch 3 signalling promotes tumour growth in colorectal
cancer. J Pathol. 224:448–60. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ye YZ, Zhang ZH, Fan XY, Xu XL, Chen ML,
Chang BW and Zhang YB: Notch 3 overexpression associates with poor
prognosis in human non-small-cell lung cancer. Med Oncol.
30:5952013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Travis WD, Brambilla E and Riely GJ: New
pathologic classification of lung cancer: Relevance for clinical
practice and clinical trials. J Clin Oncol. 31:992–1001. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Detterbeck FC, Boffa DJ and Tanoue LT: The
new lung cancer staging system. Chest. 136:260–271. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cui H, Kong Y, Xu M and Zhang H: Notch 3
functions as a tumor suppressor by controlling cellular senescence.
Cancer Res. 73:3451–3459. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Doucas H, Mann CD, Sutton CD, et al:
Expression of nuclear Notch 3 in pancreatic adenocarcinomas is
associated with adverse clinical features and correlates with the
expression of STAT3 and phosphorylated Akt. J Surg Oncol. 97:63–68.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chen Y, De Marco MA, Graziani I, et al:
Oxygen concentration determines the biological effects of NOTCH-1
signaling in adenocarcinoma of the lung. Cancer Res. 67:7954–7959.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Simon DP, Giordano TJ and Hammer GD:
Upregulated JAG1 enhances cell proliferation in adrenocortical
carcinoma. Clin Cancer Res. 18:2452–2464. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Steg AD, Katre AA, Goodman B, Han HD, Nick
AM, Stone RL, Coleman RL, Alvarez RD, Lopez-Berestein G, Sood AK
and Landen CN: Targeting the notch ligand JAGGED1 in both tumor
cells and stroma in ovarian cancer. Clin Cancer Res. 17:5674–5685.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Koukourakis MI, Giatromanolaki A, Sivridis
E, Gatter KC and Harris AL: High DLL4 expression in
tumour-associated vessels predicts for favorable radiotherapy
outcome in locally advanced squamous cell head-neck cancer (HNSCC).
Angiogenesis. 16:343–351. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu Z, Fan F, Wang A, Zheng S and Lu Y:
Dll4-Notch signaling in regulation of tumor angiogenesis. J Cancer
Res Clin Oncol. 140:525–536. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ishigami S, Arigami T, Uenosono Y, Okumura
H, Kurahara H, Uchikado Y, Setoyama T, Kita Y, Kijima Y, Nishizono
Y, et al: Clinical implications of DLL4 expression in gastric
cancer. J Exp Clin Cancer Res. 32:462013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chansky K, Sculier JP, Crowley JJ, Giroux
D, Van Meerbeeck J and Goldstraw P: International staging committee
and participating institutions: The international association for
the study of lung cancer staging project: Prognostic factors and
pathologic TNM stage in surgically managed non-small cell lung
cancer. J Thorac Oncol. 4:792–801. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Danza G, Di Serio C, Ambrosio MR, Sturli
N, Lonetto G, Rosati F, Rocca BJ, Ventimiglia G, del Vecchio MT,
Prudovsky I, et al: Notch 3 is activated by chronic hypoxia and
contributes to the progression of human prostate cancer. Int J
Cancer. 133:2577–2586. 2013.PubMed/NCBI
|
|
31
|
Chen X, Thiaville MM, Chen L, Stoeck A,
Xuan J, Gao M, Shih IeM and Wan TL: Defining Notch 3 target genes
in ovarian cancer. Cancer Res. 72:2294–2303. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Konishi J, Kawaguchi KS, Vo H, Haruki N,
Gonzalez A, Carbone DP and Dang TP: Gamma-secretase inhibitor
prevents Notch 3 activation and reduces proliferation in human lung
cancers. Cancer Res. 67:8051–8057. 2007. View Article : Google Scholar : PubMed/NCBI
|
